PD-1/PD-L1 Checkpoint in Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report

Antonella Bianchi¹*, Simona Ferrari¹, Gabriella Gullotta¹, Antonella Grasso² and Ombretta Annibali³

Received: March 05, 2018;   Published: March 16, 2018

DOI: 10.26717/BJSTR.2018.03.000865

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a rare form of malignancy that arises around mammary implants in patients undergoing prosthetic surgery. It has been included as a provisional entity in the revised WHO classification of lymphoid malignancy. The PD-1/PD-L1 axis is one of the major mechanisms of immune escaping exerted by several cancer types in which up-regulation of PD-L1 is observed. We report the presence of PD-1/PD-L1 checkpoint in a case of BI-ALCL of a 67 year old woman, whom previously had undergone mastectomy and reconstruction for breast carcinoma.

Keywords: PD-1/PD-L1; BI-ALCL; Lymphomas; Lymphoprolipherative Diseases

Abbreviations: PD-1: Programmed Death-1; PD-L1: Programmed Death-Ligand 1; BI-ALCL: Breast Implant-Associated Anaplastic Large Cell Lymphoma; ALK: Anaplastic Lymphoma Kinase; TCR: T-Cell Receptor; CHL: Classical Hodgkin’s Lymphoma; PTCL: Peripheral T-cell Lymphoma; FFPE: Fixed Formalin Paraffin Embedded

Abstract| Introduction| Case Presentation| Discussion| Conclusion| Acknowledgement| References|